Rabbit monoclonal antibody (RabMAbs): A new generation of monoclonal antibodies for research, diagnosis and treatment. Rabbit monoclonal antibody technology is currently difficult to replicate by replacing high or low affinity mouse monoclonal antibodies with high quality rabbit monoclonal antibodies.
Background
In 1995, Dr. Katherine Knight succeeded in obtaining myeloma-like tumors (plasmacytoma) in transgenic rabbits at Loyola University of Chicago. In the following years, Dr. Robert Pytela and Mr. Weimin Zhu improved the technology at UCSF to produce high-yield rabbit monoclonal antibodies. Epitomics has exclusive patents for rabbit monoclonal antibody technology and has developed a licensing platform for rabbit monoclonal antibodies for research, diagnostics and treatment.
Advantage
The emergence of rabbit monoclonal antibodies brings many benefits. First, rabbit antisera usually contain high affinity antibodies that recognize more types of epitopes than murine antisera. Second, rabbit monoclonal antibodies are capable of recognizing many antigens that do not produce immunity in mice. Third, because rabbit spleens are large, more fusion experiments can be performed, making it possible to screen high-throughput fusion cells.
Therapy
Rabbit monoclonal antibodies are used for treatment: By 2004, the market for therapeutic monoclonal antibodies is expected to be approximately $6.4 billion. It is expected that hundreds of therapeutic antibodies will be developed for the treatment of a variety of diseases in the next 10 years. Rabbit monoclonal antibody fusion cells and other proprietary Epitomics technologies provide an opportunity to release the energy of this new antibody and to create a new human monoclonal antibody for medical needs.
Diagnosis
Rabbit monoclonal antibodies as diagnostic products: For several years, it has been known that the rabbit immune system provides the best antibody reagents for diagnostic purposes. Many small compounds and peptides produce an effective immune response in rabbits. Therefore, rabbit polyclonal antibodies are used in a variety of drug screening and clinical diagnostic kits.
Drug
Rabbit monoclonal antibodies are powerful tools for drug development: complete sequencing of the human genome has greatly affected the progress of drug development. New drug development has shifted from traditional disease target selection to the systematic search for disease targets using genomic information. Protein is closer to the cause of disease than DNA or RNA. Monoclonal antibodies are the most powerful tool for detecting protein specificity and sensitivity. In addition, monoclonal antibodies are able to specifically counter or enhance the function of proteins, making them powerful tools for proteomics.
The advantages of rabbit monoclonal antibodies provide a large space for biomedical research and the development of antibody drugs. Due to the difficulty in finding specific antigens, the technically high barriers make the monotherapy therapeutic drugs difficult to be copied after the patent protection expires, and are not vulnerable to the price of generic drugs. Further development of rabbit monoclonal antibodies is expected to result in more sensitive and reliable diagnostic reagents and high quality antibody drugs.
After years of research, rabbit monoclonal antibodies have been used more and more in immunoblotting, immunohistochemistry, flow cytometry and other immunological studies.
Related service:
No comments:
Post a Comment